Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923639 | 1.00 | PTPRB (0.60) | PTPRBPTPN1 | |
| SCHEMBL16564482 | 0.87 | PTPRB (0.46) | PTPRB | |
| SCHEMBL6803371 | 0.82 | CNR1 (0.58) | — | |
| SCHEMBL468138 | 0.81 | PTPRB (0.43) | PTPRB | |
| SCHEMBL20474090 | 0.78 | PTPRB (0.77) | PTPRBPTPN1 | |
| SCHEMBL468124 | 0.78 | PTPRB (0.77) | PTPRBPTPN1 | |
| SCHEMBL468123 | 0.78 | PTPRB (0.77) | PTPRBPTPN1 | |
| SCHEMBL6803123 | 0.76 | POLB (0.48) | PTPRBPTPN1 | |
| SCHEMBL6803118 | 0.76 | POLB (0.48) | PTPRBPTPN1 | |
| SCHEMBL468276 | 0.75 | PTPRB (1.00) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038265-B1 | Human protein-tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2038265-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | claimed |
| EP-3293182-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Aerpio Therapeutics, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2592073-B1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND THEIR USE | AERPIO THERAPEUTICS INC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2592073-A2 | Human protein tyrosine phosphatase inhibitors and their use | Warner Chilcott Company, LLC (PR) | 2013-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885PTPN1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.